Basal-supported oral therapy (BOT) is often used to treat poorly controlled type 2 diabetes. However, patients sometimes experience nocturnal and early morning hypoglycemia. Thus, maintaining targeted glycemic control by BOT is limited in some patients. We assessed the efficacy and safety of replacing basal insulin by sitagliptin therapy in Japanese type 2 diabetes patients on BOT. Forty-nine subjects were sequentially recruited for the 52-week, prospective, single arm study. Patients on BOT therapy were switched from basal insulin to sitagliptin. The primary endpoint was change in HbA1c in 52-week. The secondary endpoints were dropout rate, changes in body weight, frequency of hypoglycemia, and relationship between change in HbA1c and insulin secretion capacity evaluated by glucagon loading test. The average dose of basal insulin was 15.0 ± 8.4 units. Sixteen subjects (31.3%) were dropped because replacement by sitagliptin was less effective for glycemic control. In these subjects, diabetes duration was longer, FPG and HbA1c at baseline were higher, and insulin secretion capacity was lower. Change in HbA1c in 52-week was -0.40% (95%CI -0.50 to -0.32) (P<0.05). Change in body weight was -0.71 kg (95%CI -1.42 to -0.004) (P<0.05). Frequency of hypoglycemia was decreased from 1.21 ± 1.05 to 0.06 ± 0.24 times/month. HbA1c level was improved if C-peptide index (CPI) was over 1.19. In conclusion, basal insulin in BOT can be replaced by sitagliptin with a decrease in 3 HbA1c level and frequency of hypoglycemia in cases where insulin secretion capacity was sufficiently preserved.
HbA1c level and frequency of hypoglycemia in cases where insulin secretion capacity was sufficiently preserved.
Introduction
Basal insulin preparation is recommended by the American Diabetes Association (ADA) / European Association for the Study of Diabetes (EASD) consensus algorithm when lifestyle interventions and oral glucose-lowering agents no longer achieve the glycemic goal of haemoglobin A1c (HbA1c) level less than 7% [1, 2] . Recently, two long-acting insulin analogues, insulin glargine and insulin detemir, are available that attain glycemic targets more effectively and safely [3, 4] . There are no significant differences reported in glycemic control and overall hypoglycemia between the two analogues [5] . The combination of basal insulin and oral hypoglycemic agents (OHAs), known as basal-supported oral therapy (BOT), is often used to treat poorly controlled type 2 diabetes [6, 7] . Better glycemic control, fewer hypoglycemic episodes, and less weight gain are obtained by BOT than by biphasic insulin [8] . In addition, BOT is relatively cost effective with the same glycemic control level as biphasic insulin regimen [9] . BOT is also helpful in Japanese type 2 diabetes patients. In the ALOHA (Add-on to Lantus® to OHA) study, in which 5,223 Japanese type 2 diabetes patents participated, mean HbA1c was reduced from 9.05 ± 1.15% to 7.63 ± 1.17% in 24-week [10] . Although BOT is well-tolerated and effective for glycemic control, patients sometimes experience nocturnal and early morning hypoglycemia. In the ALOHA study, glimepiride and 40 mg/day of gliclazide, which is enough for glycemic control when combined with sitagliptin [14] . Patients also show improved glycemic control even if insulin secretion capacity is insufficient for oral therapy [14, 15] . The main pathophysiology of Japanese type 2 diabetes is impairment of insulin secretion [16, 17] .
Insulin secretion capacity in Japanese populations is almost as half as that in Caucasians [18] . Especially, decreased basal and early phase insulin secretion is more contributed to Japanese type 2 diabetes [16] . Usually insulin therapy was needed in those whose C-peptide index (CPI) was lower than 0.8 [19] . However basal insulin therapy is not always ideal in some patients because postprandial glucose is still high, while preprandial glucose is low, resulting in large fluctuation in blood glucose. On the other hand, DPP-4 inhibitor could ameliorate decreased early phase insulin secretion. This encouraged us that basal insulin can be replaced with sitaglipitn in type 2 diabetes patients treated with SUs and basal insulin in some BOT cases.
We show here that sitagliptin can be switched from basal insulin in patients with C-peptide index (CPI) and/or secretory unit of islet in transplantation (SUIT) equal to or larger than 1.19 and/or 36.4, respectively, with beneficial effects on glycemic control.
MATERIALS AND METHODS

Study Design and Participants
This was a prospective, 52-week, single center, single arm, intervention study to evaluate the effects on glycemic control of replacement of basal insulin to sitagliptin in type 2 diabetes patients inadequately controlled with BOT. Outpatients of Takashima General Hospital were recruited consecutively for a sample size of 45 subjects.
Inclusion criteria were: type 2 diabetes treated with basal insulin (insulin glargine or detemir) and SUs (glimepiride or gliclazide) ± metformin ± thiazolidinedione ± -glucosidase inhibitors for more than 1 year; aged ≥ 20 years; HbA1c level ≥ 6.9%; no improvement in HbA1c ≥ 0.5% within 3 months in BOT; and a fasting C-peptide reactin (CPR) of > 0.5 ng/mL. Exclusion criteria were: type 1 diabetes; secondary diabetes; alcoholism; severe depression or severe psychological condition; malignancy; and abnormal hemoglobinemia. The study protocol was approved by the Institutional Review Board of Takashima General Hospital, and registered on University hospital Medical Information Network in Japan (UMIN000005499). Written informed consent was obtained from all subjects.
Procedures and Intervention
The duration of the study was 52 weeks. Subjects were screened for eligibility and gave basic demographic information, medical history, and frequency of hypoglycemia. Within a month before changing therapy from basal insulin to sitagliptin, glucagon loading test was performed without any OHAs or basal insulin for more than 24 h to evaluate insulin secretion capacity. When basal insulin was replaced by sitagliptin, the dosage of glimepiride or gliclazide was decreased to equal to or less than 2.0 mg/day or 40 mg/day, respectively, to prevent increased hypoglycemia if the subjects had been treated with more than 2.0 mg/day glimepiride or 40 mg/day gliclazide. If the subjects had been treated with equal to or less than 2.0 mg/day of glimepride or 40 mg/day of gliclazide, that dosage of SUs was maintained. Metformin (Met) and thiazolidinedione (TZD) were continued without any changes during the study. -glucosidase inhibitors were discontinued. The dosage of SUs was changed depending on the frequency of hypoglycemic episodes and glycemic control level. Sitagliptin was started at 50 mg/day, the usual initial dosage in Japan, which was increased to 100 mg/day if the HbA1c level did not reach 6.9%, since titration to 100 mg/day is acceptable.
Measurements
The primary endpoint was change in HbA1c in 52-week. The secondary endpoints were dropout rate due to lesser efficacy of replacement by sitagliptin of basal insulin on 
Statistical analysis
Sample size was estimated to be 34 to detect a 0.4% change in HbA1c in 52-week with a power of 95%, alpha 0.05 two-tailed, beta 0.20, standardized effect size 0.7. To take the dropout rate of 30% into account, the aim was to include 45 subjects. IBM SPSS Statistics was used for analysis. Dependent samples Student's t-test was used to compare the means of HbA1c level, insulin secretion capacity, BMI, body weight, age, and diabetes duration of the subjects between baseline and 52-week. Person's product-moment correlation test was used to evaluate the relationship between change in HbA1c and insulin secretion capacity or CPI or SUIT. To evaluate cut-off values of diabetes duration, FPG, HbA1c, 0-min CPR, 6-min CPR, delta-CPR, CPI, and SUIT, receiver operating characteristics curve (ROC) analysis was used. Independent samples Student's t-test was used to compare the mean of change in HbA1c in 52-week between subjects treated with sitagliptin + glimepirde and sitagliptin + gliclazide. Dunnett analysis was used to compare change in HbA1c in 52-week among subjects treated with sitagliptin + SUs and sitagliptin + SUs + MET and sitagliptin + SUs + TZD. P values <0.05 were considered as statistically significant.
Results
Participants
Forty-nine patients were eligible and were consecutively enrolled in the study (Table 1) .
Average age of subjects was 70.0 ± 10.2 years; ratio of male was 60.8%; duration of diabetes was 14.3 ± 8.2 years; average body weight was 62.3 ± 10.4 kg; average BMI was 24.3 ± 3.8 kg/m 2 ; and HbA1c was 7.97 ± 0.81%. All subjects were treated with SUs; 17 subjects (34.7%) were treated with glimepiride (average dose 1.67 ± 1.47 mg)
and 32 (65.3%) were treated with gliclazide (average dose 33.8 ± 12.0 mg). Average dosage of basal insulin analogues was 15.0 ± 8.4 units. Glucagon loading test showed that 0-min CPR, 6-min CPR, CPI, and SUIT were 1.65 ± 1.02 ng/mL, 3.37 ± 1.98 ng/mL, 1.19 ± 0.64, and 36.5 ± 22.1, respectively. Sixteen subjects (32.6%) were dropped due to an increase in HbA1c in 8-week; 6 (29.4%) and 11 (34.4%) were dropped in glimepiride-and gliclizaide-treated subjects, respectively ( Table 2) . No subjects were dropped for other reasons. Thirty-three subjects completed the study.
HbA1c findings and dosage of SUs and sitagliptin
Therapy adherence was confirmed by certified diabetes educators (nurses) in the study.
Adherence of BOT therapy and the switching therapy were almost 100%, and there was no different between both therapies (Data not shown).
HbA1c level in 52-week in final subjects was significantly decreased from 7.75 ± 0.70% to 7.40 ± 0.68% (P<0.01) ( Table 2 ). Change in HbA1c in 52-week was -0.40% (95%CI; -0.50, -0.32%) (P<0.05). HbA1c level in 52-week in glimepiride-treated subjects (n=12) was significantly decreased from 7.90 ± 0.85% to 7.16 ± 0.77% (P<0.01). Change in HbA1c in 52-week was -0.74% (95%CI; -1.03, -0.45%) (P<0.05).
HbA1c level in 52-week in gliclazide-treated subjects (n=21) was significantly decreased from 7.66 ± 0.60% to 7.46 ± 0.61% (P<0.05). Change in HbA1c in 52-week was -0.20% (95%CI; -0.35, -0.04%) (P<0.05). There was a significant difference in change in HbA1c in 52-week between glimepride-treated and gliclazide-treated subjects (P<0.01). The original dosages of glimepiride and gliclazide before the study were 1.58 ± 0.93 mg/day and 38.2 ± 14.0 mg/day, respectively; the initial dosages at the beginning of the study were significantly decreased to 0.96 ± 0.40 mg/day and 24.8 ± 8.7 mg/day, respectively (P<0.05); and the final dosages were significantly increased to 1.42 ± 0.57 mg/day and 31.4 ± 12.0 mg/day, respectively, compared to the initial dosages (P<0.05), and were almost equal to the original dosages (Table 2 ). Final dosage of sitagliptin was 74.2 ± 25.4 mg/day in all subjects; 70.8 ± 25.7 mg/day in glimepiride-treated subjects;
and 77.3 ± 25.5 mg/day in gliclazide-treated subjects with no significant difference between the two groups.
Of 33 subjects who completed the study, 22 subjects were treated with sitagliptin and SUs, 6 subjects were treated with sitagliptin and SUs and MET, and 3 subjects were treated with sitagliptin and SUs and TZD; changes in HbA1c in 52-week were -0.38% (95%CI; -0.58, -0.19%) (P<0.05), -0.54% (95%CI; -0.90, -0.20%) (P<0.05), and -0.23% (95%CI; -0.43, -0.04%) (P<0.05), respectively (Table 2 ). However, there was no significant difference among the three groups.
Change in body weight, BMI, and frequency of hypoglycemia
Body weight in final subjects at baseline was 64.2 ± 9.5 kg, and was decreased to 63. Frequency of hypoglycemia at baseline was 1.21 ± 1.05 times/month, and was significantly decreased to 0.06 ± 0.24 times/month at 52-week (P<0.001). Change in frequency in hypoglycemia in 52-week was -1.21 times/months (95%CI; -1.5, -0.80) (P<0.05) ( Table 3) . During the study, no severe hypoglycemia was noted.
During the study, no other adverse events were not observed after replacement of basal insulin with sitagliptin.
Differences in HbA1c findings in 8-week in the final and dropped subjects
Sixteen subjects of 49 recruited were dropped after 8-week due to increased HbA1c level. The remaining 33 subjects completed the study. HbA1c level at baseline (0-week) in final subjects was 7.75 ± 0.70%, and was significantly decreased to 7.45 ± 0.61% at 8-week (P<0.001) ( 
Differences in clinical factors in final and dropped subjects
There were no differences in age, sex, dosage of SUs, or dosage of basal insulin in final and dropped subjects (Table 4) . Body weight and BMI also were not significantly different (P=0.065 and P=0.2432, respectively). On the other hand, diabetes duration in dropped subjects was longer than that in final subjects (12.1 ± 6.6 vs. 18.7 ± 9.5 years,
P<0.05).
FPG and HbA1c also were higher in dropped subjects than in final subjects (FPG; 7.4 ± 1.5 vs. 8.9 ± 2.9 mM, P<0.05) (HbA1c; 7.75 ± 0.70 vs. 8.42 ± 0.87%, P<0.01).
Insulin secretion capacity was significantly higher in final subjects than that in dropped subjects (Table 4 ) (P<0.05). In final subjects, CPR level at 0-min, 6-min, and delta CPR (6-min CPR -0-min CPR) were 1.95 ± 1.25 ng/mL, 3.81 ± 2.13 ng/mL, and 1.98 ± 1.35 ng/mL, respectively. In dropped subjects, CPR level at 0-min, 6-min, and delta CPR were 1.37 ± 0.64 ng/mL, 2.42 ± 1.21 ng/mL, and 1.16 ± 0.69 ng/mL, respectively. CPI and SUIT index also were significantly higher in final subjects than those in dropped subjects. CPI at baseline in final subjects was 1.35 ± 0.68, while that in dropped subjects was 0.92 ± 0.51 (P<0.05). SUIT at baseline was 42.7 ± 23.0 in final subjects, and 23.1 ± 10.6 in dropped subjects (P<0.01). We examined cut-off values of diabetes duration, FPG, HbA1c, 0-min CPR, 6-min CPR, delta-CPR, CPI, and SUIT by analyzing ROC curves; they were 16.5 years, 8.2 mM, 7.8%, 1.25 ng/ml, 2.80 ng/ml, 1.60 ng/ml, 1.34, and 37.5, respectively (Fig. 1 ).This indicates that with longer diabetes duration, insulin secretion capacity becomes lower and the consequent poorer glycemic control makes switching BOT-treated patients from basal insulin to sitagliptin unsafe.
Correlation between efficacy of sitagliptin on glycemic control and insulin secretion capacity, CPI, and SUIT
We examined whether or not insulin secretion capacity, CPI, or SUIT at baseline predicted the efficacy of replacing basal insulin with sitagliptin on glycemic control (Fig. 2 ). There was a correlation between change in HbA1c at 8-week and 0-min CPR (r=-0.281), 6-min CPR (r=-0.326), and delta CPR (r=-0.290), assessed by glucagon loading test at baseline ( Fig. 2A , B, C) (P<0.05). In addition, CPI (r=-0.360) or SUIT (r=-0.306) at baseline was correlated with change in HbA1c at 8-week (Fig. 2D, E) (P<0.05). The value of 0-min CPR, 6-min CPR, delta CPR, CPI, and SUIT at which the HbA1c level was not increased by replacement of basal insulin by sitagliptin were calculated to be 1.64 ng/mL, 3.36 ng/mL, 1.71 ng/mL, 1.19, and 36.4, respectively, by
Pearson's product-moment correlation test ( Table 5 ). The value of 0-min CPR, 6-min CPR, delta CPR, CPI, and SUIT at which the HbA1c level was decreased by 0.5% in 8-week were calculated to be 1.86 ng/mL, 3.83 ng/mL, 1.98 ng/mL, 1.36, and 41.3, respectively. Other clinical characteristics of the patients such as disease duration and body weight were not significantly correlated with efficacy of replacing basal insulin with sitagliptin on glycemic control (Data not shown).
Discussion
We show here that basal insulin can be switched to sitagliptin with good effects in type 2 diabetes patients treated with BOT. With this treatment, the HbA1c level decreased from 7.75 ± 0.70% to 7.35 ± 0.68% in 52-week (P<0.01). The change in HbA1c in 52-week was -0.40% (95%CI; -0.50, -0.32) (P<0.05). The efficacy of switching to sitagliptin from basal insulin was correlated with insulin secretion capacity, CPI, and SUIT, CPI being most correlated marker in the present study. The average CPI in final subjects was 1.35 ± 0.68 ng/mL, while that of dropped subjects was 0.92 ± 0.51 ng/mL.
Pearson's product-moment correlation test revealed that HbA1c was improved by switching from basal insulin to sitagliptin if CPI was equal to or higher than 1.19 ( Fig.   2D and Table 5 ). Similarly, basal insulin could be switched to sitagliptin if SUIT was equal to or larger than 36.4 ( Fig. 2E and Table 5 ). In the dropped subjects, diabetes duration was longer, FPG and HbA1c were worse, 0-min CPR, 6-min CPR, delta-CPR, CPI, and SUIT were lower compared to those in final subjects. (Table 4 ). Cut-off values of them were 16.5 years, 8.2 mM, 7.8%, 1.25 ng/ml, 2.80 ng/ml, 1.60 ng/ml, 1.34, and 37.5, respectively (Fig. 1 ). This suggests that the efficacy of switching from basal insulin to sitagliptin, when combined with SUs, is dependent on basal glycemic control and the insulin secretion capacity. Baseline HbA1c of dropped subjects was higher than that of the final subjects. Dosage of basal insulin was more required to reach target HbA1c level in dropped subjects compared to that in the final subjects because of lower insulin secretion capacity. Thus, if baseline HbA1c level had been reduced by increasing dosage of basal insulin, it would be difficult to replace basal insulin to sitagliptin. The combination therapy of glimepiride and sitagliptin was more effective for HbA1c reduction than that of gliclazide and sitagliptin. Recently, it was reported that cAMP sensor Epac2 is a direct target of several sulfonylureas [23] . Tolbutamide, glibenclimide, and glimepiride bound Epac2 and enhanced glucose-stimulated insulin secretion.
However, gliclazide did not bind Epac2. Because Epac2 also mediates the potentiation of insulin secretion by cAMP increased by endogenous incretin, the combination therapy of glimepiride and sitagliptin more enhances insulin secretion through activation of Epac2. This might be a potential mechanism why the combination therapy of glimepiride and sitagliptin was more effective for glycemic control than that of gliclazide and sitagliptin.
Generally, insulin secretion capacity of Japanese is as half as that of Caucasian [16, 17, 18] . Therefore, more than 60% of Japanese type 2 diabetes patients are treated with SUs [24] . DPP-4 inhibitor now is one of the most popular OADs, and more than 2 million patients were treated with DPP-4 inhibitors in Japan. Based on pathophysiology of Japanese patients and the mechanism of incretin effect, the combination therapy with SUs and DPP-4 inhibitors seems to be most effective for glycemic control compared to that with other OADs and DPP-4 inhibitors. On the other hand, the main pathophysiology of Caucasian type 2 diabetes is insulin resistance compared to that of Japanese type 2 diabetes [25, 26] . Dosage of basal insulin in BOT in Caucasian patients is greater than that in Japanese patients. During the course of the disease, type 2 diabetes patients are treated with several OHAs [27, 28] . However, if the HbA1c level does not reach less than 7%, insulin treatment is considered the next step [1, 2] . BOT is often selected for outpatients because once daily injection is acceptable and the glycemic control is superior, with fewer hypoglycemic episodes and less weight gain compared to biphasic insulin [8] . In Japan, the commonly 
